Кирилл Борисович Лапшин

Кирилл Борисович Лапшин

Auto-generated profile, based on publicly available information

Кирилл Борисович Лапшин

Almazov National Medical Research Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2020 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
ABAndrei Evgen'evich Bautin
Andrei Evgen'evich Bautin
SASergey Avdeev
Sergey Avdeev
ASA. A. Seyliev
A. A. Seyliev
MSM. V. Shvechkova
M. V. Shvechkova
ZMZ. M. Merzhoeva
Z. M. Merzhoeva
ORO. A. Rozenberg
O. A. Rozenberg
The objective: to evaluate the effectiveness of inhaled surfactant therapy in the integrated treatment of severe COVID-19 pneumonia in a multicenter prospective clinical trial of surfactant-BL.Subjects and methods. 122 patients with severe COVID-19-associated pneumonia treated in two treatment centers were enrolled in the study. All of them received antiviral, anticoagulant and anti-inflammatory therapy. 56 patients also received inhalation therapy with surfactant-BL (OOO Biosurf, St. Petersburg, Russia) at a dose of 1 mg/kg 2-3 times a day. The remaining 66 patients received no surfactant-BL inhalation. When included into the study, all patients were divided into two groups based on severity of the condition at the time of inclusion: 62 people (Group I) needed oxygen inhalation through a face mask with the flow of 6-8 L/min for hypoxemia correction (27 received surfactant therapy and 35 did not); other 60 patients (Group II) required non-invasive respiratory support (constant positive airway pressure, non-invasive mechanical ventilation, high-flow oxygen therapy), of them 29 received surfactant therapy, while 31 patients did not.Results. In Group I, switching to invasive mechanical ventilation was required for 3/27 (11.1%) patients who received surfactant therapy, and 10/35 (28.6%) who received no surfactant therapy (p = 0.085); lethality made 3/27 (11.1%) and 9/35 (25.7%) (p = 0.131), respectively. In Group II, among those who received surfactant therapy, 5/29 (17.2%) were switched to invasive mechanical ventilation and 18/31 (58.1%) among those who did not receive it (p = 0.001); lethality made 5/29 (17.2%) and 18/31 (58.1%) (p = 0.001), respectively. In the pooled group of 122 patients with severe COVID-19-associated pneumonia, 8 (14.3%) of 56 patients who received surfactant died, and 27 (40.9%) of 66 died among those who did not receive it, (p = 0.001).Conclusion: Inhalation surfactant therapy can reduce the frequency of switching patients to mechanical ventilation and statistically significantly reduce lethality caused by severe pneumonia associated with SARS-CoV-2.

22 January 2025 in Pulmonary Circulation
Verified
Journal Article
Open access
NGNatalia Sergeevna Goncharova
Natalia Sergeevna Goncharova
DRDaria Ryzhkova
Daria Ryzhkova
KLKirill Lapshin
Kirill Lapshin
ARAnton Ryzhkov
Anton Ryzhkov
AMAryana Malanova
Aryana Malanova
OMOlga Moiseeva
Olga Moiseeva
Right ventricular heart failure (RV HF) is the leading cause of death in pulmonary arterial hypertension (PAH). Relevance of the low‐risk status assessment using available diagnostic tools requires a reliable confirmation. The study aimed to evaluate right ventricular perfusion and glucose metabolism using positron emission tomography (PET)/computed tomography (CT) with [13N]‐ammonia and [18F]‐fluorodeoxyglucose ([18F]‐FDG) in 30 IPAH patients (33.8 ± 9.4 years) according to ESC/ERS 2022 risk status. The ratio of SUVmaxRV/LV metabolism and SUVmaxRV/LV perfusion showed significant positive correlation with pulmonary artery pressure, right heart dilatation, NT‐proBNP level and negative correlation with the RV ejection fraction. The SUVmaxRV/LV perfusion and SUVmaxRV/LV metabolism ratios differed significantly according to risk status. Low risk patients had a SUVmaxRV/LV metabolism comparable to the controls without PH. The SUVmaxRV/LV perfusion ratio was elevated in low‐risk IPAH patients compared with controls. Increased SUVmaxRV/LV perfusion may be an early marker of coronary flow adaptation to RV pressure overload in low‐risk IPAH patients and requires further evaluation. Further long‐term studies are needed to determine the clinical relevance and cut‐off values for the RV/LV PET/CT with [13N]‐ammonia and [18F]‐fluorodeoxyglucose ([18F]‐FDG) uptake in different IPAH risk groups.

26 August 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
NGNatalia Sergeevna Goncharova
Natalia Sergeevna Goncharova
ARA. V. Ryzhkov
A. V. Ryzhkov
KLK. B. Lapshin
K. B. Lapshin
AKA. F. Kotova
A. F. Kotova
OMOlga Moiseeva
Olga Moiseeva
Aim. To compare cardiac magnetic resonance imaging (MRI) parameters with known prognosis determinants in patients with pulmonary hypertension (PH).Material and methods. This prospective single-center study included 60 patients with PH aged 21-72 years. Cardiac MRI, right heart catheterization, echocardiography, N-terminal pro-brain natriuretic peptide (NT-proBNP) and 6-minute walk test (6MWT) were assessed at baseline.Results. Significant correlations between invasive hemodynamic parameters, NTproBNP and cardiac MRI parameters were confirmed. There were no significant correlations between the right ventricular (RV) contractility, RV volume and 6MWT distance, the functional class of PH. Cardiac MRI values allowed us to reliably separate patients at low risk from those at intermediate and high risk according to the 2015 ESC/ERS score. According to multivariate regression analysis, the right ventricular end systolic volume index >54 ml/m2 (hazard ratio, 0,2; 95% confidence interval, 0,05-0,9; p=0,004) and class 3-4 PH (hazard ratio, 0,2; 95% confidence interval, 0,07-0,8; p=0,026) remained independent predictors of mortality.Conclusion. The use of cardiac MRI in low-risk patients can significantly improve the early detection of right ventricular myocardial dysfunction and contribute to the timely optimization of PH-specific therapy. During monitoring patients with PH, cardiac MRI has the potential to reduce the need for repeated invasive investigations.

31 August 2025 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
NBNadezhda V. Boyarskaya
Nadezhda V. Boyarskaya
OSOlga Skortsanu
Olga Skortsanu
DSDarya V. Smirnova
Darya V. Smirnova
NYNatalia Mikhailovna Yudintceva
Natalia Mikhailovna Yudintceva
NGNatalia Sergeevna Goncharova
Natalia Sergeevna Goncharova
ЖМЖанетта Альбековна Матакаева
Жанетта Альбековна Матакаева
Highlights The endothelial cells of the pulmonary artery are a deficient model object. Our task was to work out the method of cell isolation from the Swan-Ganz catheter described in the literature. However, no cells were obtained using this technique. We have developed an alternative technique for isolating cells from blood obtained from the lumen of the pulmonary artery during right heart catheterization, and demonstrated the suitability of this technique for routine production of endothelial cell cultures from patients with pulmonary arterial hypertension. AbstractAim. Obtaining cultures of pulmonary artery endothelial cells as a model object. The endothelium ensures the integrity of the vascular wall, and disorders of endothelial function play an important role in the development of various pathological processes. Obtaining endothelial cell cultures from fragments of various human vessels is a fairly well–developed and widely used method. However, it has limitations that relate to the availability of biological material for certain groups of patients. Thus, when studying the pathogenesis of pulmonary hypertension, fragments of the pulmonary artery are practically inaccessible to the researcher, since surgical intervention for this pathology is not a routine method of treatment.Methods. The cells were obtained from the balloon of the Swan-Ganz catheter in accordance with the descriptions in the literature, alternative tissue dissociators and different adhesive media were additionally tested. The isolation of cells from the blood from the lumen of the pulmonary artery and from the peripheral (cubital) vein was carried out by dividing the blood into fractions and washing the cells of interest according to the protocols described in the literature.Results. In this work, we tested the production of pulmonary artery endothelial cells in patients with pulmonary arterial hypertension by removing cells from the balloon of the Swan-Ganz catheter during right heart catheterization. The catheter removal method has shown its unsuitability for use in routine laboratory practice. As an alternative, we have developed a method for obtaining endothelial cells from blood taken from the lumen of the pulmonary artery during catheterization.Conclusion. Isolation of endothelial cells from blood taken from the lumen of the pulmonary artery during right heart catheterization showed the suitability of this method for routine production of endothelial cell cultures from patients with pulmonary arterial hypertension.

29 April 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MSM. A. Simakova
M. A. Simakova
SPS. I. Parkhomenko
S. I. Parkhomenko
KLK. B. Lapshin
K. B. Lapshin
TGT. D. Glebovskay
T. D. Glebovskay
DKD. V. Karpova
D. V. Karpova
OMOlga Moiseeva
Olga Moiseeva
Aim. Comparison of conservative and invasive treatment strategies in patients with intermediate-high risk pulmonary embolism (PE) based on a multimodal assessment of efficacy and safety.Material and methods. This single-center, open-label, randomized, comparative trial will include 100 patients with a verified diagnosis of PE with intermediate-high risk of 30-day mortality. Patients will be randomized 1:1 to standard anticoagulant therapy or selective low-dose alteplase transcatheter thrombolysis. Patients will be followed for 12 months. The primary endpoint is a decrease in the right ventricle to left ventricle ratio by 20% or more from baseline at 48±6 hours after initiation of therapy. There are secondary endpoints: patient hemodynamic instability; ISTH major bleeding; Qanadli index decrease at 48 hours; degree of residual thrombosis with reduced perfusion at 3-6 months; incidence of post-thromboembolic syndrome at 3-6 months; 30-day, 90-day, and 1-year mortality.Conclusion. The study will provide important clinical data on the short- and long-term efficacy and safety of different treatment approaches in patients with intermediate-to-high-risk acute pulmonary embolism.

13 March 2023 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
SPS. I. Parkhomenko
S. I. Parkhomenko
KLK. B. Lapshin
K. B. Lapshin
TGT. D. Glebovskaya
T. D. Glebovskaya
KMK. N. Malikov
K. N. Malikov
NMN. V. Marukyan
N. V. Marukyan
MSM. A. Simakova
M. A. Simakova
Selective transcatheter thrombolysis (STT) in patients with pulmonary embolism (PE) with an intermediatehigh risk of 30-day mortality is an option for rapid lung reperfusion with a decrease in right ventricular (RV) afterload, which largely determines the prognosis of patients.Objective. Comparison of the efficacy of STT using reduced doses of alteplase and routine conservative treatment of patients with PE with an intermediate-high risk of 30-day mortality using a retrospective analysis of the data from Almazov National Medical Research Centre.Design and methods. The retrospective single-center study included 45 patients (18 men (40 %) and 27 women (60 %)) admitted to the anaesthesiology and resuscitation department of the Almazov National Medical Research Centre from January 1, 2021 to May 1, 2022 with the confirmed diagnosis of acute PE. Intermediate-high risk patients (22 people (57,9 %)) were divided into two groups according to the treatment strategy: the group receiving standard anticoagulant therapy (n = 15 (68,2 %)) and the group with STT by alteplase at a total dose of 50 mg (n = 7 (31,8 %)). In order to assess the effectiveness of treatment, the main laboratory and instrumental indicators were compared based on data from the medical information system.Results. Baseline clinical characteristics of the compared groups did not differ. Systolic pressure in the pulmonary artery (SPPA) in the transcatheter treatment group decreased from 59 [50; 82] to 35 [30; 65] mmHg; in the conservative treatment group: from 65 [50; 70] to 52 [40; 59] mmHg. In the selective thrombolysis group, there was a significant trend for a greater decrease SPPA compared to the anticoagulant therapy group: –25 [–29; –3] versus — 10 [–23; –6] mmHg, р = 0,047. There was a significant change in the level of leukocytes and platelets in the group of transcatheter treatment versus anticoagulant therapy: –5,0 [6,1; 4,1] × 109/l vs –2,8 [4,3; 1,8] × 109/l (p = 0,017) and 130 [32; 181] × 1012/l vs 31 [2; 56] × 1012/l (р = 0,044). There were no significant differences in the change in the RV size between the groups. The groups did not differ in the total number of hemorrhagic complications. When bleeding was divided by severity (according to the TIMI classification), moderate bleeding was more common in the selective thrombolysis group (2 cases versus 0 with a conservative approach, p = 0,014). There were no differences in the duration of treatment in the anaesthesiology and resuscitation department and the terms of inpatient treatment.Conclusions. A single center retrospective study demonstrated the high quality of approaches to the diagnosis and treatment of PE in terms of current guidelines. The STT with reduced doses of alteplase was associated with a more significant decrease SPPA and normalization of hemogram parameters when compared to the standard treatment approach. At the same time, selective thrombolysis was associated with a higher risk of hemorrhagic complications. A prospective study of the efficacy and safety of prolonged STT with the selection of the dose of thrombolytic in patients with PE with an intermediate-high risk of 30-day mortality is needed.